托伐普坦联合呋塞米治疗慢性心肾综合征利尿剂抵抗患者的疗效观察

摘要/Abstract

摘要： 目的：观察低剂量托伐普坦联合呋塞米治疗慢性心肾综合征伴利尿剂抵抗患者的临床疗效。方法：选择伴利尿剂抵抗的慢性心肾综合征患者71例，随机分为观察组36例和对照组35例。观察组应用托伐普坦15～30 mg/d口服联合呋塞米40 mg 每日两次静脉注射；对照组应用呋塞米400 mg/d微量泵持续静脉输注。监测比较两组治疗前与治疗96 h的日尿量变化及临床疗效；记录比较两组高钠血症、肝肾功能损伤等不良反应的发生情况。结果：治疗后两组患者尿量较治疗前均增多(P<0.001)，观察组患者尿量持续增加，至72 h达高峰，此后维持相近水平；对照组患者尿量48 h达高峰，此后维持相似水平；两组患者尿量比较显示观察组48 h、72 h和96 h尿量较对照组增多（P<0.01）。观察组疗效优于对照组(P=0.026)；两组间总不良反应发生率无统计学差异（P>0.05）。结论：联合应用低剂量托伐普坦与呋塞米能有效改善慢性心肾综合征患者的利尿剂抵抗，提高临床疗效且未增加不良反应。

关键词: font-size:medium, ">心肾综合征；利尿剂抵抗；低剂量；托伐普坦；呋塞米；疗效

Abstract: Objective： To observe the therapeutic effects of low dosage tolvaptan combined with furosemide in chronic cardiorenal syndrome (CRS-2) patients with diuretic resistance (DR). Methods： 71 CRS-2 patients with DR were randomly divided into observation group (36 cases) and control group after treatment (35 cases). The observation group treated with 15-30 mg tolvaptan combined with 40 mg furosemide injection twice a day， while the control group treated with 400 mg furosemide through continuously venous transfusion. The urinary volume before and after the treatments and the therapeutic effects of the two groups were recorded and compared. Results： The daily urinary volumes of the two groups increased after treatments(P<0.001). The peak urinary volumes of the observation group was at the 72 hour after treatment and the control group was at the 48 hour after treatment. There were statistical difference between the urinary volume of the two groups(P<0.01). The observation group had better clinical effects than the control group (P=0.026).While the total adverse reactions rate showed no statistical difference between the two groups(P>0.05). Conclusion： Low dosage tolvaptan combined with furosemide could significantly alleviate the diuretic resistance and improve the clinical effects in the chronic cardiorenal syndrome patients， and without increasing adverse reactions.

Key words: font-size:medium, ">Cardiorenal syndrome； Diuretic resistance； Low dosage； Tolvaptan； Furosemid； Therapeutic effects

中图分类号:

赵炳朕, 隗颖, 张文敏, 崔建伟, 李庆一, 王林军. 托伐普坦联合呋塞米治疗慢性心肾综合征利尿剂抵抗患者的疗效观察[J]. 中国医药导刊, 2020, 22(3): 174-177.

ZHAO Bingzhen, WEI Ying, ZHANG Wenmin, CUI Jianwei, LI Qingyi, WANG Linjun. Therapeutic Effects of Tolvaptan Combined with Furosemid in the Treatment of Chronic Cardiorenal Syndrome Patients with Diuretic Resistance[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2020, 22(3): 174-177.

参考文献

[1]Yogasundaram H,Chappell MC,Braam B,et al. Cardiorenal Syndrome and Heart Failure-Challenges and Opportunities.Can J Cardiol,2019, 35(9): 1208-1219. DOI: 10.1016/j.cjca.2019.04.002.
[2]Chitturi C, Novak JE. Diuretics in the Management of Cardiorenal Syndrome. Adv Chronic Kidney Dis,2018, 25(5):425-433. DOI: 10.1053/j. ackd. 2018.08.008.
[3] Ronco C，McCullough P，Anker SD，et al．Cardiorenal syndromes:report from the consensus conference of the acute dialysis quality initiative．Eur Heart J, 2010, 31 (6): 703-711．
[4] National Renal Foundation. K/ DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification ,and stratification[ J] . Am J Renal Dis, 2002, 39( 2 Supple1):S1-266.
[5]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志, 2014, 42(2):98-122. DOI: 10.3760/ cma.j.issn.0253-3758.2014.02.004.
[6]朱丁季, 刘长华, 许顶立. 心力衰竭患者利尿剂抵抗及其防治[J].中华心血管
病杂志, 2015, 43(3): 200-202.
[7]Orvalho JS, Cowgill LD. Cardiorenal Syndrome: Diagnosis and Management. Vet Clin North Am Small Anim Pract, 2017,47(5):1083-1102. DOI: 10.1016/j.cvsm. 2017. 05.004.
[8]Verbrugge FH, Grieten L, Mullens W. Management of the cardiorenal syndrome
in decompensated heart failure. Cardiorenal Med, 2014, 4(3-4):176-188. DOI: 10.1159/ 000366168.
[9]Shah N, Madanieh R, Alkan M, et al. A perspective on diuretic resistance in chronic congestive heart failure. Ther Adv Cardiovasc Dis, 2017,11(10):271-278. DOI: 10.1177/1753944717718717.
[10]Yogasundaram H, Chappell MC, Braam B, et al. Cardiorenal Syndrome and Heart Failure-Challenges and Opportunities. Can J Cardiol, 2019, 35(9):1208- 1219. DOI: 10.1016/j.cjca.2019.04.002.
[11] Verbrugge FH, Mullens W, Tang WH. Management of Cardio-Renal Syndrome and Diuretic Resistance. Curr Treat Options Cardiovasc Med, 2016, 18(2):11. DOI: 10.1007/s11936-015-0436-4.
[12]Ikeda Y, Inomata T, Kida K, et al. Different diuretic properties between Tolvaptan and Furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR. Heart Vessels, 2019,34(3):442-451.DOI: 10.1007/s00380-018-1270-x.
[13]Tejero Hernández MA, García Martínez E, Arroyo Marin MJ, et al. Tolvaptan in a pediatric cardiorenal syndrome: What is its role? Arch Argent Pediatr, 2018 , 116(2):e279-e282. DOI: 10.5546/aap.2018.e279.
[14] Hirai K, Shimomura T, Moriwaki H, et al. Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment. Eur J Clin Pharmacol, 2016, 72(10):1177-1183.DOI: 10.1007/s00228-016-2091-4.

[1]	廖娟, 覃姣玉, 王建超, 玉叶, 文彬, 邓鑫. “以平为期”治则在治疗新冠肺炎的应用[J]. 中国医药导刊, 2020, 22(9): 593-598.
[2]	刘可可, 吴倍华, 乔依白, 姚松梅, 奚斌, 陈萌蕾, 成文武. 晚期癌症患者的社区三阶梯疼痛治疗效果评价[J]. 中国医药导刊, 2020, 22(9): 599-603.
[3]	陈小兰, 朱琪. 中医在非酒精性脂肪性肝病治疗中的运用探讨[J]. 中国医药导刊, 2020, 22(9): 604-606.
[4]	李建垒, 曹向阳, 宋永伟. 保守治疗神经根型颈椎病的研究现状[J]. 中国医药导刊, 2020, 22(9): 607-610.
[5]	吴敏, 张洁. 颞下颌关节紊乱病的针灸推拿治疗研究进展[J]. 中国医药导刊, 2020, 22(9): 611-614.
[6]	程明荣, 戴德坚. 疏血通联合乌司他丁治疗高脂血症性胰腺炎对肠道激素和脂肪因子的影响[J]. 中国医药导刊, 2020, 22(9): 615-619.
[7]	王雪芳, 孙科佳, 彭红霞. 小儿肺咳颗粒联合阿奇霉素对喘息性支气管炎患儿肺功能及炎性因子的影响[J]. 中国医药导刊, 2020, 22(9): 620-623.
[8]	黄文忠, 曹红霞. 柴胡桂枝干姜汤临床应用与认识[J]. 中国医药导刊, 2020, 22(9): 624-626.
[9]	刘大锐, 李报春. 复合型右肺大细胞神经内分泌癌1例并文献复习[J]. 中国医药导刊, 2020, 22(9): 627-630.
[10]	王永军, 王舒颖, 张婷婷, 李晗怡, 李环. 11月龄全内脏反位支气管肺炎患儿病例报告1例[J]. 中国医药导刊, 2020, 22(9): 631-633.
[11]	王权, 杨珂璐, 王铸, 田金徽, 叶颖江, 王杉, 姜可伟. 单细胞测序技术的文献计量学研究及热点应用[J]. 中国医药导刊, 2020, 22(9): 634-641.
[12]	马静, 贾红政, 田亮玉, 李文茜, 贾永涛. 基于《临床用药须知》成方制剂中地黄及其炮制品的合理应用研究[J]. 中国医药导刊, 2020, 22(9): 642-645.
[13]	吕晓峰, 周鹏, 刘瑞霞, . 我院600例呼吸科住院患者抗菌药物使用情况分析[J]. 中国医药导刊, 2020, 22(9): 646-649.
[14]	杜林林, 梁毅, 周亚娴, 陶浪, 李韬, 李慧强. 以质量管理为突破的药品智慧监管新尝试——基于贵阳信息化案例分析[J]. 中国医药导刊, 2020, 22(9): 650-653.
[15]	李丽静, 黎运达, 包淑娟, 李木子, 赵锦, 刘新成. 区块链+特许药械追溯管理的实践与思考[J]. 中国医药导刊, 2020, 22(9): 654-658.

快速检索引用检索图表检索高级检索